Description
A class I PI3K inhibitor (IC50s = 0.039, 0.036, 0.023, and 0.383 µM for p110α, -δ, -γ, and -β, respectively); selective for class I PI3Ks over Vps34, DNA-PK, and mTOR (IC50s = 6.974, 4.75, and >15 µM, respectively); inhibits proliferation of MCF-7 and PC3 cells (IC50s = 9.669 and 16.492 µM, respectively); reduces tumor growth in a BT474 breast cancer mouse xenograft model when administered alone or in combination with trastuzumab or lapatinib